Evidence map›Paper›PMID 42326510›Full record

ArticleResearch square2026

Therapeutic Effects of Nanoparticles Loaded with Combined Sense and Anti-Sense of EpoR Plasmids to Enhance Angiogenesis.

Linda Noukeu, Priyanka Iyer, Vy Tran, Amirhossein Hakamivala, Na Nguyen, Liping Tang, Kytai T Nguyen, Tam Nguyen

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Linda NoukeuDepartment of Bioengineering, The University of Texas at Arlington, Arlington, Texas 76010, USA.
Priyanka IyerDepartment of Bioengineering, The University of Texas at Arlington, Arlington, Texas 76010, USA.
Vy TranDepartment of Bioengineering, The University of Texas at Arlington, Arlington, Texas 76010, USA.
Amirhossein HakamivalaDepartment of Bioengineering, The University of Texas at Arlington, Arlington, Texas 76010, USA.
Na NguyenDepartment of Bioengineering, The University of Texas at Arlington, Arlington, Texas 76010, USA.
Liping TangDepartment of Bioengineering, The University of Texas at Arlington, Arlington, Texas 76010, USA.
Kytai T NguyenDepartment of Bioengineering, The University of Texas at Arlington, Arlington, Texas 76010, USA.
Tam NguyenDepartment of Bioengineering, The University of Texas at Arlington, Arlington, Texas 76010, USA.

Funding

Novel nanoparticles to stimulate therapeutic angiogenesis in peripheral arterial diseaseR01HL158204 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI LIU, LI, NGUYEN, KYTAI TRUONG · 2022 to 2025
$2.2M
Synergistic Upregulation of EpoR /RopE NPs for Enhancing Effective Angiogenesis to treat PADR15HL156076 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI NGUYEN, KYTAI TRUONG · 2021 to 2021
$443k
NHLBI NIH HHS R01 HL158204NHLBI NIH HHS R15 HL156076
6 · The paper itself

Abstract

We employed nanoparticle (NP) platforms to enhance the delivery of both erythropoietin receptor (EpoR) plasmids (pEpoR) and the antisense of pEpoR (pRopE) to induce angiogenesis in ischemic tissues of peripheral arterial disease (PAD). Poly (lactic-co-glycolic acid) (PLGA) NPs loaded with these plasmids were successfully fabricated and characterized. In migration assays, pEpoR/pRopE NPs exhibited a synergistic effect, significantly outperforming pEpoR NPs alone (by 3.7-fold) and pRopE NPs alone (by 2.3-fold). Furthermore, the dual-plasmid NPs significantly enhanced cell survival and facilitated tube formation compared to the VEGF-treated group. In a PAD animal model, pEpoR/pRopE NPs improved blood perfusion in ischemic limbs by 3.8-fold and increased capillary densities in the gastrocnemius muscle by 4.7-fold compared to the VEGF group. In conclusion, pEpoR/pRopE NPs successfully transfected ischemic cells, enhancing both blood perfusion and capillary densities in ischemic tissues, highlighting their therapeutic potential for PAD treatment.

Identifiers

PMID42326510
PMCPMC13278339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.